CORRECTED-KKR, Ampersand Capital in joint bid for Oxford Immunotec -sources

A consortium of private equity firms KKR & Co Inc and Ampersand Capital Partners has approached Oxford Immunotec Global Plc, a medical diagnostics company that develops tests to identify tuberculosis, with a $400 million acquisition offer, people familiar with the matter said on Thursday.